MED

MEDIFAST INC
NYSECONSUMER CYCLICALPERSONAL SERVICES

Key Statistics

Market Cap
$118.64M
P/E Ratio
EPS
$-1.82
Beta
0.68
52W High
$15.37
52W Low
$9.22
50-Day MA
$11.78
200-Day MA
$11.54
Dividend Yield
Profit Margin
-5.79%
Forward P/E
12.48
PEG Ratio
0.97

About MEDIFAST INC

Medifast, Inc. manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutrition products in the United States and Asia-Pacific. The company is headquartered in Baltimore, Maryland.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$346.10M
Gross Profit (TTM)$242.70M
EBITDA$-3.98M
Operating Margin-7.21%
Return on Equity-9.80%
Return on Assets-4.33%
Revenue/Share (TTM)$31.48
Book Value$19.28
Price-to-Book0.62
Price-to-Sales (TTM)0.34
EV/Revenue0.0096
EV/EBITDA0.32
Quarterly Earnings Growth (YoY)-87.20%
Quarterly Revenue Growth (YoY)-34.30%
Shares Outstanding$11.12M
Float$7.71M
% Insiders4.36%
% Institutions85.18%

Historical Volatility

HV 10-Day
34.89%
HV 20-Day
34.75%
HV 30-Day
37.23%
HV 60-Day
52.96%
HV Rank
48.4%

Volatility is currently contracting

Latest News

What Science-Backed Subscription Health Programs Measure Differently

The weight loss and weight management market was valued at $31.07 billion in 2025  A program can describe its results as clinically meaningful without specifying what was measured, how it was measured, or whether the measurement tool was capable of capturing the outcome being claimed DXA scanning distinguishes fat mass, lean mass, and bone mineral content with greater precision than BMI calculations and just weight number on a scale Study completion rates carry significant weight in how research findings should be interpreted BALTIMORE, MD, June 11, 2026 (GLOBE NEWSWIRE) -- Subscription health programs compete on outcome language as much as they compete on results. Terms like "clinically studied," "science-backed," "proven," and "evidence-based" appear across a wide spectrum of programs, from programs with published randomized controlled trials to those with ingredient-level pilot data.

GlobeNewsWire6/11/2026Neutral
The Human Layer in Weight Management: What OPTAVIA's Coaching Model Is Built to Do

A randomized controlled trial published in Obesity Science & Practice found that clients on the OPTAVIA Optimal Weight 5 & 1 Plan® who worked with a coach lost significantly more weight and fat than those who attempted the program without coaching support (Arterburn LM, et al., 2019) Higher retention in a weight management program is directly correlated with more significant weight loss outcomes, per a 2024 systematic review and meta-analysis OPTAVIA coaches complete a program-specific education curriculum and must pass a certification exam before supporting participants Independent research commissioned by OPTAVIA found that 96% of Americans recognize lifestyle changes are essential for weight loss and management, yet only 17% feel confident they can manage it alone BALTIMORE, MD, May 21, 2026 (GLOBE NEWSWIRE) -- OPTAVIA, a science-backed, coach-guided comprehensive metabolic health system, is built around a core principle: that structured human support changes outcomes.

GlobeNewsWire5/21/2026Neutral
Peer-Reviewed Research Is Redefining Weight Loss Program Standards

The global weight loss industry was valued at $16.3 billion in 2025, yet peer-reviewed clinical validation of program outcomes remains uneven across the category Randomized controlled trials control for the lifestyle variables and selection bias that self-reported program data cannot account for, making them the standard for evaluating whether a weight loss program itself is driving outcomes Body composition is the breakdown of fat, lean mass, and bone. It shows what weight loss is actually made up of, a distinction that scale weight alone cannot capture A coach can address the specific barriers that may cause program adherence to stall, providing an additional support compared to digital trackers and tools BALTIMORE, MD, May 15, 2026 (GLOBE NEWSWIRE) -- Client experiences and peer-reviewed research are two pillars of evidence that, at their best, reinforce each other.

GlobeNewsWire5/15/2026Neutral
Why Medifast's $15 Cash Per Share Makes It A Strong Buy

Medifast trades below net cash value, with $15 per share in cash versus a $12.60 share price, creating a compelling value floor. Coach productivity surged 19% YoY to $5,432 per coach, signaling early signs of operational turnaround despite a shrinking coach base. Cost-cutting initiatives, asset sales, and a positive operating cash flow position MED for potential profitability by Q4 2026, with a $30 million savings target.

Seeking Alpha5/13/2026Positive

More CONSUMER CYCLICAL Stocks

Data last updated: 7/9/2026